Cormorant Asset Management LP Lowers Stock Holdings in BioAge Labs, Inc. $BIOA

Cormorant Asset Management LP reduced its position in shares of BioAge Labs, Inc. (NASDAQ:BIOA) by 4.7% in the 4th quarter, HoldingsChannel reports. The institutional investor owned 2,040,605 shares of the company’s stock after selling 100,000 shares during the period. BioAge Labs makes up about 1.2% of Cormorant Asset Management LP’s portfolio, making the stock its 18th biggest holding. Cormorant Asset Management LP owned 0.06% of BioAge Labs worth $26,997,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also modified their holdings of the company. Bridgeway Capital Management LLC boosted its position in shares of BioAge Labs by 47.5% during the fourth quarter. Bridgeway Capital Management LLC now owns 77,600 shares of the company’s stock worth $1,027,000 after buying an additional 25,000 shares during the period. Schonfeld Strategic Advisors LLC purchased a new position in shares of BioAge Labs during the fourth quarter worth $680,000. AQR Capital Management LLC boosted its position in shares of BioAge Labs by 45.2% during the fourth quarter. AQR Capital Management LLC now owns 51,918 shares of the company’s stock worth $687,000 after buying an additional 16,172 shares during the period. Trexquant Investment LP purchased a new position in shares of BioAge Labs during the fourth quarter worth $520,000. Finally, Jump Financial LLC purchased a new position in shares of BioAge Labs during the fourth quarter worth $566,000.

Wall Street Analysts Forecast Growth

Several research analysts have recently commented on the company. Weiss Ratings restated a “sell (d-)” rating on shares of BioAge Labs in a research report on Friday, April 24th. Citigroup raised their price target on BioAge Labs from $15.00 to $52.00 and gave the stock a “buy” rating in a research report on Tuesday, March 10th. Roth Mkm assumed coverage on BioAge Labs in a research report on Wednesday, May 27th. They set a “buy” rating and a $36.00 price target for the company. Oppenheimer assumed coverage on BioAge Labs in a research report on Wednesday, February 25th. They set an “outperform” rating and a $60.00 price target for the company. Finally, Wall Street Zen lowered BioAge Labs from a “hold” rating to a “sell” rating in a research report on Sunday, May 17th. Six research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, BioAge Labs presently has a consensus rating of “Moderate Buy” and an average target price of $43.50.

BioAge Labs Trading Down 2.4%

NASDAQ:BIOA opened at $19.99 on Thursday. The firm has a market cap of $888.56 million, a PE ratio of -8.33 and a beta of 0.94. The stock has a fifty day moving average price of $17.35 and a 200 day moving average price of $17.31. BioAge Labs, Inc. has a 12-month low of $4.07 and a 12-month high of $24.00.

BioAge Labs (NASDAQ:BIOA) last released its earnings results on Friday, May 8th. The company reported ($0.52) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.71) by $0.19. The firm had revenue of $2.77 million during the quarter. BioAge Labs had a negative return on equity of 29.40% and a negative net margin of 871.75%. Equities analysts forecast that BioAge Labs, Inc. will post -2.68 EPS for the current year.

About BioAge Labs

BioAge Labs (NASDAQ: BIOA) is a clinical-stage biotechnology company focused on discovering and developing therapies that address age-associated diseases. The company leverages its proprietary analytics platform to mine large-scale human biological data for insights into the molecular mechanisms of aging. By targeting fundamental aging pathways, BioAge aims to create interventions that extend healthspan and treat conditions that disproportionately affect older populations.

At the core of BioAge’s operations is its integrated drug discovery platform, which combines human omics datasets, machine learning algorithms and experimental validation to identify novel drug targets.